依那西普辅助治疗强直性脊柱炎34例疗效观察

目的：对比观察依那西普和常规药物治疗强直性脊柱炎的临床疗效，分析依那西普的临床应用价值以及安全性。方法选取2011年12月～2012年12月期间在我院住院治疗的强直性脊柱炎患者34例作为研究对象。随机分为实验组和对照组，对照组患者给予常规治疗，实验组患者在常规治疗的基础上再给予依那西普，对比两组患者的临床疗效以及不良反应的发生情况。结果两组组内治疗前后的BASDAI评分、BASFI评分、晨僵时间、夜间背痛VAS、总体背痛VAS、红细胞沉降率以及C-反应蛋白值相比差异具有统计学意义（P＜0.05），两组治疗前的BASDAI评分、BASFI评分、晨僵时间、夜间背痛VAS、总体背痛VAS、红细胞沉降率以及C-反应蛋白值相比差异无统计学意义（P＞0.05），两组治疗后的BASDAI评分、BASFI评分、晨僵时间、夜间背痛VAS、总体背痛VAS、红细胞沉降率以及C-反应蛋白值相比差异具有统计学意义（P＜0.05）。两组并发症的发生率比较差异具有统计学意义（P＜0.05）。结论依那西普治疗强直性脊柱炎的疗效显著，并发症低，安全性高。

Observation of the adjunctive treatment effect of etanercept on ankylosing spondylitis

Objective To comparatively observe the clinical effect of Etanecept and Common drugs on Ankylosing Spondylitis（AS）, and to analyze the clinical application value and safety. Methods 34 cases of AS patients who were admitted into our hospital from Dec. 2011 to Dec. 2012 were selected as the research subject and divided into test group and control group randomly, the control group was treated with general therapy, while the test group treated with Etanercept in addition to general therapy. The clinical effect and adverse reaction were comparatively studied. Results The NASDAI, BASFI scores, morning stiffness time, night back pain VAS, total back pain VAS, erythrocyte sedimentation rate, C-reactive protein value of within two groups before and after treatment had no statistical difference （P＆gt;0.05）, while the value of each indicator after the treatment had a statistical difference （P＆lt;0.05）. The complications occurrence rate of two groups has astatistical difference（P ＆lt; 0.05）. Conclusion Etanercept has an obvious effect on AS, and has a less complication rate and high safety.